SI2197883T1 - Derivat kateholamina uporaben za zdravljenje parkinsonove bolezni - Google Patents

Derivat kateholamina uporaben za zdravljenje parkinsonove bolezni

Info

Publication number
SI2197883T1
SI2197883T1 SI200831554T SI200831554T SI2197883T1 SI 2197883 T1 SI2197883 T1 SI 2197883T1 SI 200831554 T SI200831554 T SI 200831554T SI 200831554 T SI200831554 T SI 200831554T SI 2197883 T1 SI2197883 T1 SI 2197883T1
Authority
SI
Slovenia
Prior art keywords
parkinson
disease
treatment
derivative useful
catecholamine derivative
Prior art date
Application number
SI200831554T
Other languages
English (en)
Slovenian (sl)
Inventor
Morten Jorgensen
Benny Bang-Andersen
Ask Puschl
Niels Mork
Jennifer Larsen
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39877715&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2197883(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of SI2197883T1 publication Critical patent/SI2197883T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/08—Aza-anthracenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Portable Nailing Machines And Staplers (AREA)
  • Indole Compounds (AREA)
SI200831554T 2007-08-31 2008-08-28 Derivat kateholamina uporaben za zdravljenje parkinsonove bolezni SI2197883T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200701250 2007-08-31
EP08784472.6A EP2197883B1 (en) 2007-08-31 2008-08-28 Catecholamine derivative useful for the treatment of parkinson's disease
PCT/DK2008/050214 WO2009026934A1 (en) 2007-08-31 2008-08-28 Catecholamine derivatives useful for the treatment of parkinson' s disease

Publications (1)

Publication Number Publication Date
SI2197883T1 true SI2197883T1 (sl) 2016-01-29

Family

ID=39877715

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200831554T SI2197883T1 (sl) 2007-08-31 2008-08-28 Derivat kateholamina uporaben za zdravljenje parkinsonove bolezni

Country Status (29)

Country Link
EP (4) EP2195291A1 (OSRAM)
JP (4) JP5548125B2 (OSRAM)
KR (3) KR20100051834A (OSRAM)
CN (3) CN101842354A (OSRAM)
AR (2) AR068044A1 (OSRAM)
AU (2) AU2008291426B2 (OSRAM)
BR (2) BRPI0815894A2 (OSRAM)
CA (2) CA2691961C (OSRAM)
CL (2) CL2008002558A1 (OSRAM)
CO (2) CO6270232A2 (OSRAM)
CY (1) CY1117326T1 (OSRAM)
DK (1) DK2197883T3 (OSRAM)
EA (2) EA018413B1 (OSRAM)
ES (1) ES2557485T3 (OSRAM)
HR (1) HRP20151334T1 (OSRAM)
HU (1) HUE025882T2 (OSRAM)
IL (1) IL203080A (OSRAM)
MX (1) MX2010002210A (OSRAM)
MY (2) MY148948A (OSRAM)
NZ (2) NZ583551A (OSRAM)
PL (1) PL2197883T3 (OSRAM)
PT (1) PT2197883E (OSRAM)
RS (1) RS54470B1 (OSRAM)
SG (1) SG184711A1 (OSRAM)
SI (1) SI2197883T1 (OSRAM)
TW (2) TWI404702B (OSRAM)
UA (2) UA98804C2 (OSRAM)
WO (2) WO2009026934A1 (OSRAM)
ZA (2) ZA200909191B (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI404702B (zh) * 2007-08-31 2013-08-11 Lundbeck & Co As H 兒茶酚胺衍生物和其前藥
US8067410B2 (en) 2008-06-27 2011-11-29 H. Lundbeck A/S Phenolic and catecholic amines and prodrugs thereof
EP2303851A1 (en) * 2008-06-27 2011-04-06 H. Lundbeck A/S Novel phenolic and catecholic amines and prodrugs thereof
TW201036949A (en) * 2009-02-27 2010-10-16 Lundbeck & Co As H Treatment of dyskinesia related disorders
TW201035054A (en) * 2009-02-27 2010-10-01 Lundbeck & Co As H Methods of administering (4aR, 10aR)-1-n-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol and pharmaceutical compositions thereof
KR102712887B1 (ko) 2017-11-24 2024-10-02 하. 룬드벡 아크티에셀스카브 파킨슨병의 치료에 사용하기 위한 새로운 카테콜아민 전구약물
WO2020070099A1 (en) 2018-10-02 2020-04-09 H. Lundbeck A/S Administration of catecholamine prodrugs in combination with a 5-ht2b antagonist
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) * 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
CN113677675B (zh) * 2019-05-21 2024-07-26 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药
JP7562562B2 (ja) * 2019-05-21 2024-10-07 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
US12398106B2 (en) 2019-05-21 2025-08-26 H. Lundbeck A/S Catecholamine carbamate prodrugs for use in the treatment of parkinson's disease
EP3972970A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
CN114478298B (zh) * 2020-11-12 2024-09-27 成都西岭源药业有限公司 一种造影剂碘佛醇的纯化方法
WO2022106352A1 (en) 2020-11-17 2022-05-27 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
CN113620760A (zh) * 2021-09-07 2021-11-09 张家口思睿凯科技有限公司 一种电子盐反应液和不饱和芳香烃类化合物的还原方法
WO2025078574A1 (en) * 2023-10-12 2025-04-17 Integrative Research Laboratories Sweden Ab NOVEL ESTERS OF 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[g]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080456A (en) * 1971-10-26 1978-03-21 Schering Aktiengesellschaft Diacylapomorphines
CH648300A5 (en) * 1979-06-22 1985-03-15 Sandoz Ag Phenanthrene derivatives and medicaments containing them
US4543256A (en) * 1982-03-17 1985-09-24 Northeastern University (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers
WO1990012574A1 (en) * 1989-04-25 1990-11-01 Northeastern University Dopamine agonist compounds
JPH03163078A (ja) * 1989-08-30 1991-07-15 Sankyo Co Ltd 光学活性な縮環複素環化合物及びその製法
TW357143B (en) * 1995-07-07 1999-05-01 Novartis Ag Benzo[g]quinoline derivatives
EP0861234A1 (en) * 1995-11-10 1998-09-02 Novo Nordisk A/S Enantiomers of cis-benz e]indole compounds, their preparation and utility as dopamine-d3 receptor selective agents
CN1241998A (zh) * 1996-10-30 2000-01-19 伊莱利利公司 苯并[f]喹啉酮的合成
SE0102036D0 (sv) 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
SE0002934D0 (sv) * 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
AR030357A1 (es) * 2000-08-18 2003-08-20 Lundbeck & Co As H Derivados 4 -, 5 -, 6 - y 7-indol
US20050090518A1 (en) * 2003-10-24 2005-04-28 Nastech Pharmaceutical Company Inc. Method for treating parkinson's disease using apomorphine and apomorphine prodrugs
TWI404702B (zh) * 2007-08-31 2013-08-11 Lundbeck & Co As H 兒茶酚胺衍生物和其前藥

Also Published As

Publication number Publication date
KR20100046111A (ko) 2010-05-06
CN101687878A (zh) 2010-03-31
AU2008291426A1 (en) 2009-03-05
RS54470B1 (sr) 2016-06-30
BRPI0813456A2 (pt) 2014-12-23
EA201070327A1 (ru) 2010-08-30
AR068045A1 (es) 2009-10-28
WO2009026935A1 (en) 2009-03-05
CL2008002564A1 (es) 2009-07-17
AR068044A1 (es) 2009-10-28
HRP20151334T1 (hr) 2016-01-01
HUE025882T2 (en) 2016-04-28
JP2014148528A (ja) 2014-08-21
KR101597367B1 (ko) 2016-02-24
DK2197883T3 (en) 2016-01-11
EP2197883A1 (en) 2010-06-23
SG184711A1 (en) 2012-10-30
CY1117326T1 (el) 2017-04-26
JP2010536889A (ja) 2010-12-02
TW200914426A (en) 2009-04-01
IL203080A (en) 2014-11-30
KR20100051834A (ko) 2010-05-18
BRPI0815894A2 (pt) 2015-02-24
CO6260082A2 (es) 2011-03-22
ZA201001422B (en) 2011-06-29
CL2008002558A1 (es) 2009-08-07
ZA200909191B (en) 2011-03-30
UA97989C2 (uk) 2012-04-10
CA2691961A1 (en) 2009-03-05
TWI404702B (zh) 2013-08-11
CA2691961C (en) 2013-12-17
PL2197883T3 (pl) 2016-03-31
EP2195291A1 (en) 2010-06-16
EA200971107A1 (ru) 2010-06-30
MX2010002210A (es) 2010-03-17
CN101842354A (zh) 2010-09-22
NZ582379A (en) 2011-08-26
AU2008291425A1 (en) 2009-03-05
CN107253956A (zh) 2017-10-17
UA98804C2 (ru) 2012-06-25
CO6270232A2 (es) 2011-04-20
EA018413B1 (ru) 2013-07-30
AU2008291425B2 (en) 2012-12-06
EP2662358A1 (en) 2013-11-13
NZ583551A (en) 2012-07-27
JP2014111635A (ja) 2014-06-19
JP5548125B2 (ja) 2014-07-16
AU2008291426B2 (en) 2013-01-31
EP2197883B1 (en) 2015-11-18
JP5802792B2 (ja) 2015-11-04
CA2697688A1 (en) 2009-03-05
KR20150115963A (ko) 2015-10-14
PT2197883E (pt) 2016-02-02
JP2010536890A (ja) 2010-12-02
TW200911752A (en) 2009-03-16
EA018011B1 (ru) 2013-04-30
WO2009026934A1 (en) 2009-03-05
MY148948A (en) 2013-06-14
ES2557485T3 (es) 2016-01-26
MY179527A (en) 2020-11-10
EP3009437A1 (en) 2016-04-20

Similar Documents

Publication Publication Date Title
PT2197883E (pt) Derivados de catecolamina úteis para o tratamento da doença de parkinson
IL205153A0 (en) Compositions for treating parkinson's disease
ZA201100034B (en) Pharmaceutical compositions for treatment of parkinson's disease
ZA201008484B (en) Rasagiline for parkinson's disease modification
EP2382176A4 (en) USE OF CURCUMIN ANALOGUES CONTAINING NITROGEN FOR THE TREATMENT OF ALZHEIMER'S DISEASE
IL194076A0 (en) Imidazolothiazole compounds for the treatment of disease
ZA201006868B (en) Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease
IL209896A0 (en) Compounds for treating symptoms associated with parkinson's disease
SI2056842T1 (sl) Modificiran galaktosil-ceramid za zdravljenje kancerogenih obolenj
ZA201005116B (en) 6.7-dialkoxy ouinazoline derivatives useful for treatment of cancer related disorders
ZA200809857B (en) Terphenyl derivatives for treatment of alzheimer's disease
IL204954A0 (en) Metabotropic glutamate receptor modulators for the treatment of parkinson's disease
EP2320939A4 (en) TISSUE CALLICLE FOR THE TREATMENT OF PARKINSON DISEASE
IL213120A0 (en) Method for treating parkinson' s disease
PL1982178T3 (pl) Sposoby leczenia zaburzeń afektywnych
WO2010085799A9 (en) Compositions and method for the treatment of parkinson's disease
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
EP2214488A4 (en) COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE AND RELATED DISORDERS
ZA200907251B (en) Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to parkinson's disease
EP1863510A4 (en) METHOD FOR TREATING PARKINSON DISEASE
HK1147194A (en) Compositions for treating parkinson's disease
IL209804A0 (en) Pharmaceutical compositions for treatment of parkinson's disease
HK1158070A (en) Tissue kallikrein for the treatment of parkinson's disease
HK1175364A (en) Methods for treating parkinson's disease
GB0724947D0 (en) Composition for the treatment of psychiatric disorders